if the FDA switches to approving drug development/manufacturing processes, rather than the final products themselves, mRNA vaccines could be made on-demand, quickly enough to do this.
for instance, CAR-T immunotherapy is such a process. no patient's dose is the same, since it involves removing T-lymphocytes from the patient, genetically modifying them in a bespoke way, and putting them back in. if the process itself weren't approved, you'd need to run clinical trials on every individual dose.
pipeline approvals are probably at least a decade away, though it'd be very smart if the government would get it all ready in case we need it.
As an added bonus, if you're having a slow quarter or two, you can arrange for new demand for your products to suddenly spring up in some random corner of the world.
for instance, CAR-T immunotherapy is such a process. no patient's dose is the same, since it involves removing T-lymphocytes from the patient, genetically modifying them in a bespoke way, and putting them back in. if the process itself weren't approved, you'd need to run clinical trials on every individual dose.
pipeline approvals are probably at least a decade away, though it'd be very smart if the government would get it all ready in case we need it.